On May 22, 2020 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that interim Phase 1 data for HPN424 for prostate cancer will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 Virtual Scientific Program on May 29, 2020 (Press release, Harpoon Therapeutics, MAY 22, 2020, View Source [SID1234558418]). The poster presentation will show interim data for HPN424 from its ongoing dose escalation Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). HPN424 targets prostate-specific membrane antigen (PSMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC) platform designed to recruit a patient’s own immune cells to target and kill tumor cells.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Full details of the presentation are as follows:
Abstract/Poster Title: First-in-human, Phase 1 study of HPN424, a tri-specific half-life extended PSMA-targeting T cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: Johanna Bendell, M.D., et al.
Session: Genitourinary Cancer – Prostate, Testicular, and Penile
Date and Time: May 29, available on demand beginning at 8 a.m. ET
Abstract / Poster Number: 5552 / 133
Location: ASCO (Free ASCO Whitepaper) Meeting Library at View Source
A copy of the presentation will be available on the company’s website at View Source." target="_blank" title="View Source." rel="nofollow">View Source
Conference Call and Webcast
Harpoon’s management will host a webcast and conference call at 4 p.m. ET / 1 p.m. PT on Friday, May 29, 2020 to review the data and provide an update on other pipeline programs. The live call may be accessed by dialing:
877-407-9716 for domestic callers
201-493-6779 for international callers
A live webcast of the call will be available from the Events and Presentations section of the company’s website at View Source and will be archived there shortly after the live event.
About the Phase 1 Clinical Trial for HPN424
This Phase 1 trial is a multicenter, open-label study designed to evaluate the safety, tolerability, pharmacokinetics and activity of HPN424 in patients with mCRPC who are progressing. The trial is titled, "A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy." For additional information about the trial, please visit www.clinicaltrials.gov using the identifier NCT03577028.
The initial phase of the trial is a dose escalation phase, with the goal of determining a recommended dose for the expansion phase of the trial. HPN424 is being administered to patients once weekly by intravenous infusion. The primary outcome measures are an assessment of safety and tolerability, pharmacokinetics, and determination of a dose for the expansion phase of the trial. Secondary endpoints include overall response rate, progression free and overall survival, and duration of response. The expansion portion of the trial will further evaluate the safety and activity of HPN424 in patients with mCRPC.